A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Sponsor
Stemline Therapeutics